Kistamicin B is a natural antibiotic compound that belongs to the class of aminoglycosides. It is produced by certain strains of the bacterium Micromonospora, which is known for its ability to synthesize various bioactive metabolites. Kistamicin B exhibits antibacterial properties, particularly against Gram-positive bacteria, making it of interest in the field of medicinal chemistry and antibiotic development. The compound's mechanism of action typically involves inhibiting protein synthesis by binding to the bacterial ribosome, which disrupts the translation process. Kistamicin B is characterized by its complex molecular structure, which includes multiple functional groups that contribute to its biological activity. Its potential therapeutic applications are being explored, especially in the context of combating antibiotic-resistant infections. However, like many antibiotics, the use of kistamicin B may be limited by factors such as toxicity, resistance development, and pharmacokinetic properties. Further research is necessary to fully understand its efficacy, safety profile, and potential applications in clinical settings.

kistamicin B

155683-51-5: Kistamicin B is a natural antibiotic compound that belongs to the class of aminoglycosides. It is produced by certain strains of the bacterium Micromonospora, which is known for its ability to synthesize various bioactive metabolites. Kistamicin B exhibits antibacterial properties, particularly against Gram-positive bacteria, making it of interest in the field of medicinal chemistry and antibiotic development. The compound's mechanism of action typically involves inhibiting protein synthesis by binding to the bacterial ribosome, which disrupts the translation process. Kistamicin B is characterized by its complex molecular structure, which includes multiple functional groups that contribute to its biological activity. Its potential therapeutic applications are being explored, especially in the context of combating antibiotic-resistant infections. However, like many antibiotics, the use of kistamicin B may be limited by factors such as toxicity, resistance development, and pharmacokinetic properties. Further research is necessary to fully understand its efficacy, safety profile, and potential applications in clinical settings.

Kistamicin B exhibits antiviral properties, with ID50 values against influenza virus in MDCK cells and herpes simplex virus being 1.8 μg/mL and 30 μg/mL, respectively.

CAS 155683-51-5

kistamicin B

Kistamicin B

Ref: TM-TN10605